| Name | Citalopram |
| Description | Citalopram (Lu 10-171 is an orally active, selective serotonin reuptake inhibitor (SSRI), a selective 5-hydroxytryptamine reuptake inhibitor, and a racemic mixture of the S(+)-enantiomer (Escitalopram) and the R(-)-enantiomer.Citalopram exhibits antidepressant activity and enhances serotonergic neurotransmission. It can be used to study Alzheimer's disease. |
| In vitro | Citalopram exhibits concentration-dependent cytotoxicity when applied at concentrations ranging from 25 to 175 μM for 24 hours[4]. Specifically, at a concentration of 100 μM for 24 hours, Citalopram strongly downregulates the expression of MYBL2, BIRC5, BARD1, AURKA, CCNA2, and CCNE1 in B104 cells[4]. |
| In vivo | Administered via intraperitoneal injection at doses ranging from 5 to 40 mg/kg, Citalopram reduces immobility time in DBA/2J mice but does not elicit a similar effect in C57BL/6J mice[3]. |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40 mg/mL (123.31 mM), Sonication is recommended.
10% DMSO+90% Corn Oil : 2 mg/mL (6.17 mM), Sonication is recommended.
|
| Keywords | serotonin reuptake | Citalopram | 5HTReceptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Alverine citrate | Sevoflurane | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | 1,8-Cineole | Dopamine hydrochloride | Cloperastine hydrochloride | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine | Doxepin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Toxic Compound Library | Drug Repurposing Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
